Squamous cell carcinoma or squamous proliferation associated with nivolumab treatment for metastatic melanoma

Area of Science:

• Oncology
• Immunology
• Dermatology

Background:

• Nivolumab is an immune checkpoint inhibitor targeting programmed death-1 (PD1).
• It is approved for treating various cancers, including metastatic melanoma.
• While effective, nivolumab can cause immune-related adverse events.

Observation:

• A patient undergoing nivolumab treatment for metastatic melanoma developed a new condition.
• The patient was diagnosed with squamous cell carcinoma.
• This occurred despite the established efficacy of nivolumab in melanoma treatment.

Findings:

• The case presents a rare immune-related adverse event associated with nivolumab.
• Squamous cell carcinoma emerged as a potential side effect in this patient.
• This finding expands the known spectrum of nivolumab's side effects.

Implications:

• Clinicians should be aware of the expanding side effect profile of nivolumab.
• Early recognition and management of immune-related adverse events are crucial.
• Further research may be needed to understand the mechanisms behind this specific adverse event.